Home › Posts tagged Pembrolizumab [Keytruda]
Blog Archives

Variables of prospective response rates of PD-1/PD-L1 based therapies across cancers

Posted on by by Posted in Genetic Background, Genetic Predisposition, New Research, On The Horizon, Personalized Medicine, Thasso Post, Theragenomic Medicine No Comments ↓

August 28, 2019 – Immune checkpoint inhibitor (ICI) therapy is a form of cancer immunotherapy. The therapy targets immune checkpoints, key regulators of the immune system that when stimulated can dampen the immune response to an immunologic stimulus.

…

Read more ›

Tags: , , , , , , , , , , , , , , ,

Cancer therapies: Immune checkpoint inhibitors may kill you

Posted on by by Posted in Adverse Drug Reaction [ADR], New Research, New Safety Information, Thasso Post, Theragenomic Medicine No Comments ↓

…

Read more ›

Tags: , , , , , , , , , , , , , , , , , ,

Pembrolizumab (Keytruda): Clinical trials on hold

Posted on by by Posted in Adverse Drug Reaction [ADR], Regulatory Announcement, Thasso Post, Theragenomic Medicine No Comments ↓

September 2, 2017 – The American Food & Drug Administration (FDA) has announced that two clinical trials with Pembrolizumab (Keytruda) in patients with multiple myeloma have been put on hold. The FDA informs the public, health care professionals, and oncology clinical investigators about the risks associated with the use of Pembrolizumab (Keytruda) in combination with dexamethasone and an immunomodulatory agent (Lenalidomide (Revlimid) or Pomalidomide (Pomalyst)) for the treatment of patients with multiple myeloma.

…

Read more ›

Tags: , , , , , , , , , , ,

Biomarker-guided Larotrectinib for all cancer types?

Posted on by by Posted in Genetic Background, Genetic Predisposition, New Research, On The Horizon, Personalized Medicine, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓

June 09, 2017 –  It’s only a couple of days that the American Food & Drug Administration (FDA) approved for the first time a cancer treatment for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e.,

…

Read more ›

Tags: , , , , , , , , , ,

First cancer treatment for any solid tumor with MSI-H or dMMR approved

Posted on by by Posted in Genetic Background, New Indication Approval, Personalized Medicine, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine No Comments ↓
May 24, 2917 – The American Food & Drug Administration (FDA) just approved a major extension of the clinical indications for Pembrolizumab (Keytruda). For the first time,  a cancer treatment has been approved for any solid tumor, irrespective of the tumor’s original location, as long as the targeted tumor is carrying a specific genetic feature (i.e.,

…

Read more ›

Tags: , , , , , , , , ,

Risk of severe if not fatal skin reactions with Pembrolizumab (Keytruda)

Posted on by by Posted in Adverse Drug Reaction [ADR], New Safety Information, Regulatory Announcement, Thasso Post, Theragenomic Medicine 1 Comment ↓

March 21, 2017 – Health Canada just communicated this important safety information: Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) under treatment of patients with Pembrolizumab (Keytruda) have been reported internationally in the clinical trials and post-marketing setting.

…

Read more ›

Tags: , , , , , ,

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

Posted on by by Posted in Genetic Background, New Research, On The Horizon, Thasso Post, Theragenomic Medicine No Comments ↓

September 06, 2016 – Genetic mutations associated with acquired resistance to PD-1 blockade in melanoma have been suspected to be involved in the clinical observation that while approximately 75% of objective responses to anti–programmed death 1 (PD-1) therapy in patients with melanoma are durable, lasting for years,

…

Read more ›

Tags: , , , , , , , , , ,

Pembrolizumab [Keytruda] for advanced melanoma: First PD-1 blocking drug to receive approval

Posted on by by Posted in New Drug Approval, Thasso Post, Theragenomic Medicine 1 Comment ↓

September 11, 2014 – The U.S. Food and Drug Administration today granted accelerated approval to Pembrolizumab (Keytruda) for treatment of patients with advanced or unresectable melanoma who are no longer responding to other drugs.

Melanoma, which accounts for approximately 5 percent of all new cancers in the United States,

…

Read more ›

Tags: , , , ,

thasso: donate

thasso: conditions

thasso: newest tweets

 

thasso: recent comments

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

RSS random genetics

  • Genomic adaptations to a rice-based diet mitigate the risk of obesity and diabetes September 21, 2020
    The traditional rice-based diet of some east-Asian population has brought a number of genomic adaptations that may contribute to mitigating the spread of diabetes and obesity. An international study led by the University of Bologna and published in the journal Evolutionary Applications has recently suggested this interesting hypothesis. Researchers analyzed and compared the genomes of […]
  • Researchers identify genetic factors associated with hand-foot syndrome in chemotherapy with capecitabine September 21, 2020
    Capecitabine is a chemotherapy drug used for breast and colorectal cancer. It can extend survival rate by nearly 10%. However, recent studies revealed that almost 50% of patients develop palmar-plantar erythrodysesthesia, a skin reaction also called hand-foot syndrome with mild to serious symptoms. Up to 17% of these patients can have a burning pain in […]
  • Gene therapy corrects the cardiac effects of Friedreich's ataxia September 18, 2020
    Gene therapy was successfully used to overcome the cardiac effects of Freidreich's ataxia (FA) in a mouse model of the disease, as reported in the peer-reviewed journal Human Gene Therapy.
  • Algorithms uncover cancers' hidden genetic losses and gains September 17, 2020
    Understanding the specific mutations that contribute to different forms of cancer is critical to improving diagnosis and treatment. But limitations in DNA sequencing technology make it difficult to detect some major mutations often linked to cancer, such as the loss or duplication of parts of chromosomes.
  • Researcher finds keys to control the 'driver of cancer's aggressiveness' September 17, 2020
    'Do not erase.' 'Recycle me.' 'Free to a good home.' Humans post these signs to indicate whether something has value or not, whether it should be disposed of or not. Inside our cells, a sophisticated recycling system uses its own enzymatic signs to flag certain cells for destruction—and a different set of enzymes can remove […]

RSS random science

  • Awareness of COVID-19 in severe dementia patients September 21, 2020
    Tokyo, September 21, 2020- The ongoing coronavirus disease 2019 (COVID-19) pandemic has substantially affected patients with dementia and their caregivers.
  • Cleveland Clinic study finds no link between influenza vaccine and COVID-19 risk September 21, 2020
    Using patient data from Cleveland Clinic's COVID-19 registry, Dr. Joe Zein found that receiving the flu vaccine does not increase risk for COVID-19 or worsen associated disease outcomes, suggesting it is safe and advisable to receive the influenza vaccine this flu season.
  • Bio-based inhibition of gas hydrate formation September 21, 2020
    Copper stearate was used as the basis for this catalyst test and showed efficiency for in-situ oil combustion.
  • Biodiversity hypothesis called into question September 21, 2020
    How can we explain the fact that no single species predominates? A generally accepted hypothesis is that a trade-off exists between organisms able to acquire and consume more food than other when resources are scarce, and organisms which rapidly consume large quantities of food when they are in abundance. However, when scientists from the University […]
  • A faster and more reliable method to categorize olive oil is validated September 21, 2020
    Classifying olive oils into the categories of extra virgin (EVOO), virgin (VOO) and lampante (LOO) is still quite a challenge to deal with since the official method includes physical-chemical and sensory analyses by means of a panel of tasters. These tasters need to be specialized, and on many occasions are not available, in addition to […]
Top